US Patent

US7994185 — Benzene sulfonamide thiazole and oxazole compounds

Composition of Matter · Assigned to GlaxoSmithKline LLC · Expires 2030-01-20 · 4y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects thiazole and oxazole sulfonamide compounds, compositions containing them, and processes for preparing and using them as pharmaceutical agents.

USPTO Abstract

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

Drugs covered by this patent

dabrafenib-mesylate (DABRAFENIB MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2296`	—	dabrafenib-mesylate
`U-2296`	—	dabrafenib-mesylate

Patent Metadata

Patent number: US7994185
Jurisdiction: US
Classification: Composition of Matter
Expires: 2030-01-20
Drug substance claim: Yes
Drug product claim: Yes
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.